Overview

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept
Pharmaceutical Solutions